Changes of TSH-Stimulation Blocking Antibody (TSBAb) and Thyroid Stimulating Antibody (TSAb) Over 10 Years in 34 TSBAb-Positive Patients with Hypothyroidism and in 98 TSAb-Positive Graves’ Patients with Hyperthyroidism: Reevaluation of TSBAb and TSAb in TSH-Receptor-Antibody (TRAb)-Positive Patients

Figure 1

The changes of TSBAb in 34 TSBAb-positive patients with hypothyroidism (Table 1, I). Among the 34 TSBAb-positive patients with hypothyroidism, 17 patients continued to have persistently positive TSBAb and continued to have hypothyroidism (Table 1, Ia) (a). Half of the 34 TSBAb-positive patients continued to have persistently positive TSBAb, continued to have hypothyroidism, and did not recover from hypothyroidism. They continued to take thyroxine (T4). TSBAb disappeared in 15 of the 34 TSBAb-positive patients with hypothyroidism (Table 1, Ib) (b). Recovery from hypothyroidism was noted with the disappearance of TSBAb in 13 (87%) of the 15 patients, in whom TSBAb had disappeared. (c1, c2) show the changes of TSBAb and TSAb, respectively, in the 2 patients with TSBAb-positive hypothyroidism, who developed TSAb-positive Graves’ hyperthyroidism (Table 1, Ic). In these 2 patients, TSBAb was dominant initially (c1), and then TSAb became dominant (c2); 2 patients with TSBAb-positive hypothyroidism developed TSAb-positive Graves’ hyperthyroidism. Hypothyroidism was treated with thyroxine (T4). Graves’ hyperthyroidism was treated with 1-methyl 2-mercapto imidazole (MMI). TSBAb: TSH-stimulation blocking antibody; TSAb: thyroid stimulating antibody.